Answers are grounded in this paper and cite their sources.
Nanoplatform enhances immune activation and therapy effectiveness against CRC, indicating a potential treatment strategy.
The Se@PDA@HA@CDDP nanoplatform couples CD44-targeted chemo-photothermal therapy with immune activation to overcome redox-buffered CRC microenvironments. The graphical abstract was created with BioRender.com.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: